# A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants

> **NCT07254728** · PHASE1 · COMPLETED · sponsor: **Vaxart** · enrollment: 76 (actual)

## Conditions studied

- Norovirus Infections

## Interventions

- **BIOLOGICAL:** VXA-G1.1-NN
- **BIOLOGICAL:** VXA-G2.4-NS
- **BIOLOGICAL:** Placebo Tablets

## Key facts

- **NCT ID:** NCT07254728
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-27
- **Primary completion:** 2024-12-13
- **Final completion:** 2024-12-13
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07254728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07254728, "A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07254728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*